We’ve moved

The Rosalind and Morris Goodman Cancer Institute can now be found at www.goodmancancer.ca

Visit the new site


George Zogopoulos, M.D., Ph.D.

Academic title(s): 

Associate Professor/Professeur Associé
Rosalind and Morris Goodman Cancer Institute
Departments Oncology and Surgery
Research Institute of the McGill University Health Centre (RI-MUHC)
Faculty of Medicine and Health Sciences
McGill University

Hepato-Pancreato-Biliary and Abdominal Organ Transplant Surgery
Division of General Surgery
McGill University Health Centre (MUHC)

George Zogopoulos, M.D., Ph.D.
Contact Information

1160 Pine Avenue West
Montreal, Quebec H3A 1A3
Lab: Room 611

Office: McGill University Health Centre, EM2.3210, 1001Decarie Blvd., Montreal, Quebec, H4A 3J1

514-934-1934, ext. 36306
Fax number: 
Email address: 
george.zogopoulos [at] mcgill.ca
Awards, honours, and fellowships: 

1. 2016 Clinical Research Scholar (Junior 2), Fonds de recherche du Québec – Santé

2. 2012 Clinical Research Scholar (Junior 1), Fonds de recherche du Québec – Santé

Current research: 

Dr. Zogopoulos’ lab studies the genetics and oncogenomics of pancreaticobiliary cancers. His research includes discovery of genetic associations with familial pancreatic cancer, and therapeutic opportunities for pancreaticobiliary cancers driven by homologous recombination deficiency.

To pursue his research interests, Dr. Zogopoulos established and directs the Quebec Pancreas Cancer Study (QPCS), a familial patient registry and biospecimen repository for pancreatic, biliary tract and peri-ampullary malignancies. His program’s resources also include patient-derived tumour xenograft and cell-line libraries.

His translational research program is integrated into the ambulatory oncology clinics at the McGill University Health Centre to facilitate access to genetic counseling and testing as well as precision oncology and early detection opportunities for patients with pancreaticobiliary cancers.

Dr. Zogopoulos is the Pancreatic Disease Oriented Group co-Chair of the Canadian Cancer Trials Group (CCTG), and his research activities also include the pan-Canadian Pancreatic Cancer Profiling for Individualized Care (EPPIC) study, the Quebec Consortium for Novel Cancer Therapeutics and Biomarkers, the Pancreatic Cancer Genetic Epidemiology (PACGENE) consortium, and the Pancreatic Cancer Early Detection (PRECEDE) consortium.

His clinical practice focuses on the surgical treatment of pancreatic, biliary and hepatic malignancies, as well as abdominal organ transplantation with a focus on transplant oncology. 

Quebec Pancreas Cancer Study

Back to top